RECRUITING

The Ambient Light Multiple Myeloma Study

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The aim of this multi-site randomized control trial will be is to assess the impact Systematic lighting on circadian rhythm entrainment, Inflammation, Neutropenic Fever and Symptom Burden among Multiple Myeloma Patients undergoing Autologous Stem Cell Transplantation. To achieve this aim, 200 multiple myeloma patients will receive one of two different light-treatments that are designed to promote circadian rhythm alignment. While receiving these light treatments, participants' sleep efficiency, urine melatonin levels, blood inflammatory cytokine levels and symptoms will be assessed over a 2-month period.

Official Title

Systematic Light Exposure Effects on Circadian Rhythms Entrainment, Inflammation, Neutropenic Fever and Symptom Burden Among Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation

Quick Facts

Study Start:2023-02-13
Study Completion:2027-06-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05737732

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:21 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Multiple Myeloma diagnosis
  2. * Scheduled to undergo their first Autologous Stem Cell Transplant procedure.
  3. * 21years or older
  4. * Able to provide informed consent.
  5. * English-language proficient
  1. * Previous Autologous Stem Cell Transplant procedure
  2. * Pregnancy
  3. * Eye diseases which limit the ability of light to be processed
  4. * Secondary cancer diagnosis within the last 5 years
  5. * Severe sleep disorders
  6. * History of bipolar disorder or manic episodes
  7. * Severe psychological impairment
  8. * Previous use of light therapy
  9. * Active infection including COVID-19 infection

Contacts and Locations

Study Contact

Barbara Plitnick, BSN
CONTACT
518 242-4603
Barbara.Plitnick@mountsinai.org
Mariana Figueiro, PhD
CONTACT
518-366-9306
Mariana.Figueiro@mountsinai.org

Principal Investigator

Mariana Figueiro, PhD
PRINCIPAL_INVESTIGATOR
Icahn School of Medicine at Mount Sinai

Study Locations (Sites)

Icahn Schoool of Medicine at Mount Sinai
New York, New York, 10029
United States
Memorial Sloan Kettering Cancer Center
New York, New York, 10065
United States

Collaborators and Investigators

Sponsor: Icahn School of Medicine at Mount Sinai

  • Mariana Figueiro, PhD, PRINCIPAL_INVESTIGATOR, Icahn School of Medicine at Mount Sinai

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-02-13
Study Completion Date2027-06-30

Study Record Updates

Study Start Date2023-02-13
Study Completion Date2027-06-30

Terms related to this study

Additional Relevant MeSH Terms

  • Multiple Myeloma